This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunogenicity and Safety of AdCLD-CoV19-1 OMI as a Booster: A COVID-19 Preventive Vaccine in Healthy Volunteers (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05993325
Recruitment Status : Not yet recruiting
First Posted : August 15, 2023
Last Update Posted : August 18, 2023
Sponsor:
Information provided by (Responsible Party):
Cellid Co., Ltd.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The immunogenicity and safety of AdCLD-CoV19-1 OMI (5.0x10^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old and above will be evaluated. Outcome assessment will be performed in comparison with Comirnaty Bivalent.

Condition or disease Intervention/treatment Phase
COVID-19 Vaccines Biological: AdCLD-CoV19-1 OMI Biological: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran) Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 4000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A Phase III Multinational, Multicenter, Observer-Blinded, Randomized, Active-Controlled Trial to Evaluate the Immunogenicity and Safety of the Preventive COVID-19 Vaccine AdCLD-CoV19-1 OMI Administered as a Booster to Adults Aged 19 Years Old and Above
Estimated Study Start Date : September 2023
Estimated Primary Completion Date : May 2024
Estimated Study Completion Date : May 2025

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: 1 dose of AdCLD-CoV19-1 OMI
Test group will receive 1 dose of AdCLD-CoV19-1 OMI
 Biological: AdCLD-CoV19-1 OMI
3000 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular administration in the deltoid muscle
Active Comparator: 1 dose of Comirnaty Bivalent
Control group will receive 1 dose of Comirnaty Bivalent
 Biological: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)
1000 participants will receive investigational product (Comirnaty Bivalent) via intramuscular administration in the deltoid muscle


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Ratio of GMT of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration [ Time Frame: At 28 days post IP administration ]

    Ratio of GMT of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration (GMT of AdCLD-CoV19-1 OMI / GMT of Comirnaty Bivalent).

    Geometric mean titer (GMT): The value of multiplying the antibody titer of all available subjects (N) and take the Nth order root value.


  2. Difference in seroresponse rate (SRR) of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration [ Time Frame: At 28 days post IP administration ]

    Difference in seroresponse rate (SRR) of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration (SRR of AdCLD-CoV19-1 OMI - SRR of Comirnaty Bivalent).

    Seroresponse rate (SRR): Proportion of subjects whose antibody titer rise at least 4-fold at the measurement point compared to baseline. The titer is defined as half of detection limit if the titer before administration is below detection limit.



Secondary Outcome Measures :
  1. SRR (proportion of subject who achieved seroresponse), GMT, GMFR of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 26, 52 weeks post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration. [ Time Frame: At 26, 52 weeks post IP administration ]
    SRR (proportion of subject who achieved seroresponse), GMT (Geometric mean titer), GMFR (Ratio of GMT or GMC rise at the measurement point compared to baseline) of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 26, 52 weeks post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration.

  2. Differences in SRR, GMT, GMFR of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration by serostatus of SARS-CoV-2 N protein antibody. [ Time Frame: At 28 days post IP administration ]
    Differences in seroresponse rate (SRR), geometric mean titer (GMT), geometric mean fold rise (GMFR) of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration by serostatus of SARS-CoV-2 N protein antibody.

  3. Differences in SRR, GMT, GMFR of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration by country. [ Time Frame: At 28 days post IP administration ]
    Differences in seroresponse rate (SRR), geometric mean titer (GMT), geometric mean fold rise (GMFR) of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration by country.

  4. Proportion of immediate adverse events (AE) [ Time Frame: Within 30 minutes post IP administraiton ]
    Immediate adverse events occurred within 30 minutes (2 hours for ≥75 years old) post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration.

  5. Proportion of solicited local and systemic AE [ Time Frame: Within 7 days (Days 0 - 6) post IP administration ]
    Solicited AEs occurred within 7 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration.

  6. Proportion of unsolicited AE [ Time Frame: Within 28 days (Days 0 - 27) post IP administration ]
    Unsolicited AEs occurred within 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration.

  7. Proportion of SAE [ Time Frame: Throughout the study duration, 12 months post IP administration ]
  8. Proportion of Adverse Event Of Special Interest (AESI) [ Time Frame: Throughout the study duration, 12 months post IP administration ]
  9. Proportion of Medically-Attended Adverse Events (MAAE) [ Time Frame: Throughout the study duration, 12 months post IP administration ]
  10. Proportion of clinically significant changes in clinical laboratory tests [ Time Frame: At 28 days post IP administration ]
  11. Proportion of clinically significant changes in vital signs [ Time Frame: At 28 days post IP administration ]
  12. Proportion of clinically significant changes in physical examination [ Time Frame: At 28 days post IP administration ]

Other Outcome Measures:
  1. SRR, GMT, GMFR of SARS-CoV-2 Wuhan strain and Variants of concern (VOC) neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration. [ Time Frame: At 28 days post IP administration ]
  2. SRR, GMT, GMFR of SARS-CoV-2 B.1.1.529 S protein-specific antibody measured by ELISA at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration. [ Time Frame: At 28 days post IP administration ]
  3. Cellular immune response (CMI) measured by ELISpot at 28 days, 26, 52 weeks post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration. [ Time Frame: At 28 days, 26, 52 weeks post IP administration. ]
    Cellular immune response (CMI: responder rate, spot-forming unit) measured by ELISpot at 28 days, 26, 52 weeks post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration.

  4. Differences of SRR, GMT, GMFR of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration by previous COVID-19 vaccination series. [ Time Frame: At 28 days post IP administration ]
  5. Differences of SRR, GMT, GMFR of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration by age. [ Time Frame: At 28 days post IP administration ]
  6. Proportion of COVID-19 cases confirmed by antigen test from 14 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration to the end of the study. [ Time Frame: Throughout the study duration, 12 months post IP administration ]
  7. Proportion of severe COVID-19 cases from 14 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration to the end of the study. [ Time Frame: Throughout the study duration, 12 months post IP administration ]
  8. Proportion of hospitalization due to COVID-19 cases from 14 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration to the end of the study. [ Time Frame: Throughout the study duration, 12 months post IP administration ]
  9. Proportion of mortality due to COVID-19 cases from 14 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration to the end of the study. [ Time Frame: Throughout the study duration, 12 months post IP administration ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Individual aged 19 and above and willing to provide written informed consent to participate study voluntarily.

  2. Individual fall under one or more of the following at the date of IP administration

    • At least past 16 weeks (112 days) without additional COVID-19 vaccination since the last COVID-19 vaccination.
    • At least past 16 weeks (112 days) since the release of quarantine due to COVID-19 confirmation.
  3. Individual who agrees to use medically acceptable contraceptive methods† for at least 4 weeks prior to screening and 12 weeks post IP administration.
  4. Individual who agrees not to donate or transfuse blood (including whole blood, plasma components, platelet components, platelet plasma components) throughout the study participation.

Exclusion Criteria:

  1. Individual fall under one or more of the following at the date of IP administration

    • History of COVID-19 within 16 weeks (-111~0 days) or considered to be infected prior to IP administration.
    • History of receiving COVID-19 vaccine within 16 weeks (-111~0 days) prior to IP administration.
  2. Clinically significant abnormalities on clinical laboratory tests, electrocardiograms, and chest X-rays performed during screening visit.
  3. Positive HIV test result on the screening test.
  4. Acute febrile illness with (≥38°C), or any suspected infectious diseases, or COVID-19-like symptoms (cough, shortness of breath, chills, myalgia, headache, sore throat, loss of taste/smell, etc.) within 3 days prior to administration of IP.

  5. Any serious medical or psychiatric disease which in opinion of investigator judges unable to participate.

    • Respiratory diseases: Asthma, Chronic Obstructive Pulmonary Disease (COPD), active or latent tuberculosis which require medication, or individual who has received treatment due to worsening of the listed respiratory disease within 5 years prior to administration of IP.
    • Serious cardiovascular diseases: Congestive heart failure, coronary artery disease, myocardial infarction, uncontrolled hypertension, thrombocytopenia or venous thrombosis, capillary leakage syndrome, myocarditis, pericarditis, etc.
    • Neurologic diseases: Epilepsy, seizure within past 3 years, migraine, stroke, encephalopathy, Guillain-Barre Syndrome, encephalomyelitis, transverse myelitis, etc.
    • Malignant cancer diagnosed within past 5 years (skin basal cell and squamous cell carcinoma are excluded).
    • Immune function disorders including autoimmune hypothyroidism, psoriasis.
    • Immunodeficiency diseases.
    • History of dependently administering psychotropic drugs or narcotic analgesics within 24 weeks prior to administration of IP, or psychiatric disease or behavioral impairment that, in the opinion of the investigator, could interfere with the participant's ability to participate in the study.
    • Other hepatobiliary, renal, endocrine, urinary tract, muscular skeletal diseases which the investigator considers clinically significant.
  6. History of splenectomy.
  7. Known history of allergic or hypersensitivity to the components of IP.
  8. Known history of serious adverse reaction, allergies or hypersensitivity related to vaccination.
  9. Individual with history of bleeding diathesis or thrombocytopenia, or history of severe bleeding or bruising after intramuscular injection or venipuncture or is receiving an anticoagulant (Individual receiving low dose aspirin (less than 100mg/day) can be enrolled in judgement of investigator).
  10. History of hereditary or idiopathic angioneurotic edema.
  11. History of systemic urticaria within 5 years prior to administration of IP.
  12. Individual with history of solid organ or bone marrow transplantation.
  13. Individual who is suspected or with history of drug or alcohol abuse within 24 weeks prior to administration of IP.
  14. History of licensed drug for COVID-19 prevention aside from COVID-19 vaccine within 52 weeks prior to administration of IP.

  15. Use of immunosuppressive or chronic use of systemic steroids within 6 weeks prior to administration of IP (Topical steroids, nasal spray and inhalers are allowed).

    • Immunosuppressive: Azathioprine, Cyclosporine, Interferon, G-CSF, Tacrolimus, Everolimus, Sirolimus, Cyclophosphamide, 6-Mercaptopurine, Methotrexate, Rapamycin, Leflunomide, etc.
    • Chronic steroid: >10 mg/day prednisone equivalent for periods exceeding 14 days.
  16. Individual who has administered other investigational product or device within 24 weeks prior to screening visit.
  17. Individual who has received or planned to receive any other vaccines within 28 days prior and after the administration of IP (Flu vaccines can be administered up to 14 days prior to the date of IP administration).
  18. Receipt of immunoglobulin or blood-derived products within 12 weeks prior to administration of IP.
  19. Individual with scheduled surgery throughout the study period.
  20. Pregnant or lactating women.

  21. Individual directly related to the investigator and meets the following:

    • Personnel relationship or subordinate-superior relationship (employees of the investigator's department, staffs of this trial).
    • Students or researchers in the immediate department of the school to which the investigator belongs (e.g., medical university).
  22. Individual who is unfit for this study for any other reason in judgement of investigator.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05993325


Contacts
Layout table for location contacts
Contact: Wuhyun Kim, D.V.M whkim@cellid.co.kr
Contact: Hayeon Joo, Bachelor hyjoo@cellid.co.kr

Locations
Layout table for location information
Korea, Republic of
Dong-a University Hospital
Busan, Korea, Republic of
Kyungpook National University Hospital
Daegu, Korea, Republic of
Chungnam National University Hospital
Daejeon, Korea, Republic of
Chonnam National University Hospital
Gwangju, Korea, Republic of
Hallym University Dongtan Sacred Heart Hospital
Gyeonggi-do, Korea, Republic of
Korea University Ansan Hospital
Gyeonggi-do, Korea, Republic of
The Catholic University of Korea, ST. Vincent's Hospital
Gyeonggi-do, Korea, Republic of
Gachon University Gil Medical Center
Incheon, Korea, Republic of
Inha University Hospital
Incheon, Korea, Republic of
Hallym University Kangnam Sacred Heart Hospital
Seoul, Korea, Republic of
Korea University Guro Hospital
Seoul, Korea, Republic of
Samyook Medical Center
Seoul, Korea, Republic of
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Seoul, Korea, Republic of
Veterans Health Service Medical Center
Seoul, Korea, Republic of
Sponsors and Collaborators
Cellid Co., Ltd.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Cellid Co., Ltd.
ClinicalTrials.gov Identifier: NCT05993325    
Other Study ID Numbers: COVENT-202
First Posted: August 15, 2023    Key Record Dates
Last Update Posted: August 18, 2023
Last Verified: August 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Cellid Co., Ltd.:
COVID-19
SARS-CoV-2
Omicron
B.1.1.529
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Infections
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases